2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148600
    HTS13286 727359-12-8 98.98%
    HTS13286 is a novel AQP9 inhibitor. HTS13286 prevents the LPS-induced increase of NO. HTS13286 reduces glucose output. HTS13286 can be used in the research of endotoxin shock.
    HTS13286
  • HY-148610
    LDH-IN-2 893739-96-3 98%
    LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1).
    LDH-IN-2
  • HY-148617
    ALDH2 modulator 1 1629615-99-1 98%
    ALDH2 modulator 1 is a potent and orally active aldehyde dehydrogenase-2 (ALDH2) modulator. ALDH2 modulator 1 reduces blood alcohol levels in mice.
    ALDH2 modulator 1
  • HY-148684
    AMPK activator 10 1914176-03-6 98%
    AMPK activator 10 is an orally active, potent AMPK activator with EC150 of 44.3 nM by cell-ELISA. AMPK activator 10 increases the phosphorylation levels of ACC. AMPK activator 10 exhibits a glucose lowering effect.
    AMPK activator 10
  • HY-148689
    SPC4061 1018108-22-9
    SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases.
    SPC4061
  • HY-14874S
    Topiroxostat-d4 2732868-49-2 98%
    Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
    Topiroxostat-d4
  • HY-148752
    TRPV1 activator-2 17514-11-3 98%
    TRPV1 activator-2 (compound 9), a capsaicin head analog, makes specific interactions with channel residues at the lipid-water.
    TRPV1 activator-2
  • HY-148766
    VU661 37648-76-3 98%
    VU661, a phenazine carboxamide, is a modulator of circadian rhythms to produce a period lengthening of the circadian rhythm. VU661 is a redox-active small molecule .
    VU661
  • HY-148795
    Ritivixibat 2460667-52-9 98%
    Ritivixibat is an apical sodium-dependent bile acid transporter (ASBT/IBAT) inhibitor. Ritivixibat blocks ASBT/IBAT function, thereby reducing bile acid reabsorption, regulating bile acid homeostasis and alleviating liver injury. Ritivixibat protects cholangiocytes from damage caused by cytotoxic bile acids. Ritivixibat is applicable to research related to primary sclerosing cholangitis.
    Ritivixibat
  • HY-148846
    Mosapride N-Oxide 1161443-73-7 98%
    Mosapride N-Oxide is a major active metabolite of Mosapride. Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.
    Mosapride N-Oxide
  • HY-148850
    AZD-2207 866598-45-0 98%
    AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permeability in the Caco-2 model and can be used in research related to type 2 diabetes and obesity.
    AZD-2207
  • HY-14885R
    Eliglustat (Standard) 491833-29-5 98%
    Eliglustat (Standard) is the analytical standard of Eliglustat. This product is intended for research and analytical applications. Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    Eliglustat (Standard)
  • HY-14885S
    Eliglustat-d15 tartrate 1884556-84-6 98%
    Eliglustat-d15 (tartrate) is the deuterium labeled Eliglustat. Eliglustat tartrate is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    Eliglustat-d15 tartrate
  • HY-148869
    Hexanoyl-coenzyme A 5060-32-2 98%
    Hexanoyl-coenzyme A (R-Hexanoyl-CoA) is a coenzyme A derivative.
    Hexanoyl-coenzyme A
  • HY-148874
    FXR antagonist 2 1660153-21-8 98%
    FXR antagonist 2 (compound A-26) is a diarylamide derivative, as well as a moderate FXR antagonist. FXR antagonist 2 can be used in the study of hyperlipidemia and type 2 diabetes.
    FXR antagonist 2
  • HY-148922
    PPARα/γ agonist 2 2213365-56-9 98%
    PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent.
    PPARα/γ agonist 2
  • HY-148926
    HSD17B13-IN-1 2770246-02-9 98%
    HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-1
  • HY-14892C
    Gemigliptin hydrochloride 1523530-62-2 98%
    Gemigliptin hydrochloride is the hydrochloride salt of Gemigliptin (HY-14892). Gemigliptin hydrochloride is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin hydrochloride exhibits potent anti-glycation properties. Gemigliptin hydrochloride can be used for the research of advanced glycation end products (AGE)-related diabetic complications.
    Gemigliptin hydrochloride
  • HY-148936
    GLX481372 1990478-58-4 98%
    GLX481372 is a NADPH Oxidase (NOX) inhibitor. GLX481372 potently inhibits NOX4/5 activities with IC50 values of 0.68 and 0.57 μM. GLX481372 also has weak inhibitory activity against NOX1, NOX2, and NOX3, with IC50 values of 7, 16 and 3.2 μM respectively. GLX481372 can inhibit ROS production. GLX481372 can be used for the researches of inflammation, cardiovascular and metabolic disease, such as diabetes.
    GLX481372
  • HY-149043
    NIK-IN-1 1451079-18-7 98%
    NIK-IN-1 (Compound 2) is an inhibitor of NF-κB-inducing kinase (NIK). NIK-IN-1 is used for research on hepatic inflammatory diseases and acute liver injury.
    NIK-IN-1
Cat. No. Product Name / Synonyms Application Reactivity